DDInter825 DDInter915
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Glimepiride {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) palliates {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvoxamine
Fluvoxamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvoxamine
Fluvoxamine {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Glimepiride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aminoglutethimide
Aminoglutethimide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Glimepiride {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Glimepiride (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Indacaterol (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Indacaterol (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) palliates asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)